|Company name||NextGeM Inc.|
|Kobe Lab.||6-3-5 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047|
|Tokyo Lab.||#601 2-24-13 kami-oosaki, Shinagawa-ku, Tokyo 141-0021|
|Director||Masakazu Nakajima, Masanori Miyanishi, Haruhisa Hirosaki|
|Business purpose||Development of next generation regenerative medicine innovation using stem cell|
Developing the next generative medicine using tissue stem cells and creating a platform where many young, promising and entrepreneurial scientists can realize its full potential
NextGeM Inc. has been established with the aim of providing the ultimate curative treatment method with limited side effects, focusing on the possibility which tissue stem cells have, and making full use of their potential.
Adverse reactions tend to be significant especially when doctors give treatment which have high curative effect. In other words, the best treatment policy for the doctors may not be necessarily the best option for their patients.
In order to cope with this gap between them, NextGeM Inc is trying to develop a next generation medical platform which can bring out the best therapeutic effect without affecting the patient's quality of life (QOL) which will help more patient to get high quality, less side effects and safe regenerative medical cure.
At the same time, social and industrial structure are rapidly globalized, and technological innovation are transforming our institutional, social and cultural norms, disrupting the conventional industrial fields faster than expected. We are thinking that it is obviously becoming important to maximize the use of these state-of-the-art technologies and create new values.
Creating new values in this way is the most sought-after thing in Japan today and the same can be said in the scientific research world. In order to make full use of the leading edge technology and to survive the coming fierce global competition, establishing a new platform involving a wide range of stakeholders across industry, academia, government and borders, will be an urgent issue.
On the other hand, the working environment around young scientists with full of a new, innovative and bold idea is extremely severe. Our secondary but important mission is to prepare an exciting, risk-tolerant and thrill-seeking platform where young and entrepreneurial scientists can realize its full potential, and to generate a role model for their career development.
Representative Director CEO Masakazu Nakajima
Representative Director CSO Masanori Miyanishi
Co-founder, Chief Executive Officer
Masakazu is a co-founder and serves as Chief Executive Officer of NextGeM, having 20+ years of working experience specializing in business incubation/ development, venture capital / private equity investment and cross border M&As around Asia-Pacific time zone including Japan. After graduated from Kyoto University engineering department, joined ITOCHU Corporation, where he was responsible for project development and business investment in Asia. After that, he was in charge of corporate planning department at Cyber Agent Inc., venture capital, private equity and range of alternative investment at Schroder Ventures and Macquarie Capital around Asia Pacific. Most recently, he runs, as a founder, Brightlink Partners Inc., engaging in seed/ early stage investment, business development and cross boarder M&As to incubate series of start-ups including healthcare/ medical space.
Co-founder, Chief Scientific Officer, MD., Ph.D
Masanori is a co-founder and serves as the Chief Scientific Officer of NextGeM. He also leads a basic science research group at RIKEN BDR conducting fundamental research on the hematopoietic stem cell. His passion for stem cell biology stems from his work with Irving L. Weissman at Stanford University, where he developed, along with NextGeM co-founder (James) to reshape how we purify and study the true hematopoietic stem cell. Their work was published in Nature in 2016. Masanori is also a physician-scientist, with clinical specialization in OBGYN, earned his M.D. and Ph.D. in Molecular biology and Immunology from Kyoto University, published his thesis regarding macrophage biology in Nature in 2007, and was appointed as an Assistant Professor at Kyoto University in 2011. He has spent nearly 15 years in the basic research including Stem Cell Biology and has authored numerous publications.
Director, Development Strategy
After graduating from faculty of Pharmaceutical Science, Osaka University, Hirosaki joined Fujisawa Pharmaceutical Co., Ltd. (present: Astellas Pharma Inc.). He served as a Director of International Coordination, Clinical Research Center of Fujisawa Research Institute of America, Inc. (Chicago) and a Senior Vice President of Global Planning & Administration, Astellas Pharma Global Development. After those responsibilities, he became a Corporate Executive and a Japan & Asia Development Head. He developed Cephem antibiotics, antifungal agent Micafungin®, and led the clinical development of many drugs including immunosuppressant Prograf®, used for suppressing rejection reactions in organ transplantation. He has been a board Director of NextGeM since April 2018.
Chief Infomation Strategy Officer
Graduating from Kyoto University Graduate School of Electric Engineering, joined NTT DATA Corporation. Since 2000 in charge of solution development at Cyber Agent Inc, led the establishment and promotion of new business, built up recruitment, training and evaluation system, laid the base of the company's media business. After served IT Division of MUFG Bank, Ltd., established violascape Co., Ltd. as founder/CEO and engaged in projects related to IT solutions,IT consulting, and planning, development, management of digital contents. Also he had a lot of experience of AI(machine learning/natural language processing) project.
MD., Ph.D, Chief Scientist
He is graduated as a Medical Doctor from Gadjah Mada University (Indonesia) in 2002, and became a Clinical Pathologist in 2008. His Ph.D was awarded by Kyoto University Graduate School of Medicine in 2014. He continued as a postdoctoral researcher in Kyoto University Graduate School of Medicine (2014-2016) and in Keio University School of Medicine (2016-2017). In 2017, he is appointed as an Adjunct Assistant Professor of Institute for Advanced Medical Research-Keio University School of Medicine. He continued his carrier in NextGeM Inc. from October 2018.
James Y. Chen
Co-founder & Scientific Advisor
James is a co-founder and serves as a Scientific Advisor for NextGeM. He previously served as the Director of Translational Medicine at Forty Seven Inc., a public clinical-stage biotech company ($FTSV) focused on developing novel anti-cancer therapies targeting the CD47-SIRPa axis. He is currently completing his residency at the Massachusetts General Hospital and Harvard Medical School, he earned his M.D. and Ph.D. in Stem Cell Biology and Regenerative Medicine under Irving L. Weissman from Stanford University, and B.S. in Microbiology, Immunology, and Molecular Genetics, summa cum laude, from the University of California Los Angeles (UCLA). He has spent nearly 15 years in stem cell biology and hematology and has authored numerous publications including in Nature, Cell, and the New England Journal of Medicine
Sef P. Kurstjens
M.D., Ph.D.,Exective Advisor
Most recently served as Chief Medical Officer at Astellas Pharma Inc, from 2013-2018. There he had responsibility for Development, Regulatory Affairs, Medical Affairs, Pharmacovigilance and Quality Assurance and was a member of the Corporate Executive Committee. Dr. Kurstjens was the President and Chief Executive Officer at Agensys, Inc., an early stage oncology Astellas affiliate, from 2010 to 2013. Prior to joining Astellas, Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development at Allergan Inc since 2007. He entered the pharmaceutical industry with Sandoz Pharma (now Novartis) in Basel in 1991 and has held positions of increasing responsibility in his 12 years with Pfizer in both Europe and the US, including Worldwide Therapeutic Area Head of Gastrointestinal and Genitourinary, and Clinical Side Head. Dr. Kurstjens received his qualifications in medicine and physiology from University of the Witwatersrand Medical School in Johannesburg, South Africa.
After graduating from the faculty of Social Sciences of Hitotsubashi University, Joji Hattori worked for Itochu Corporation, subsequently A.T.Kearney, before joining Roland Berger in 2003.At Roland Berger, he was stationed in Tokyo office, Shanghai Office, Dusseldorf Office, and Frankfurt Office.Then he joined Takeda Pharmaceutical Company as a Senior Director, before rejoining Roland Berger.
Business Development Manager
After graduating from faculty of Pharmaceutical Sciences, Kyoto University, Keiji joined Roland Berger, Europe's largest strategy consulting farm. He supported business / technical strategy formulation and execution for major pharmaceutical / medical equipment / consumer goods companies. After that, he turned to the Japanese Organization for Medical Device Development, Inc. (JOMDD), an incubator specialized in healthcare, engaged in business development in advanced technology fields including regenerative medicine and digital health.
IRB（Institutional Review Board)
In promoting the research, We are concerned with the ethical principles of medical research, compliance with ethical principles of medical research, and consideration on animal welfare, including the viewpoints of compliance with laws, along with the ethical sense of life-threatening as well as the most important issues and recognition doing. Based on this recognition, we have established the "Human organization research ethics committee" and "Animal experiment ethics committee" and operate it.
6-3-5 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047
#601 2-24-13 kami-oosaki, Shinagawa-ku, Tokyo 141-0021